BioCryst Pharmaceuticals, Inc. (BO1.F)
| Previous close | 4.70 |
| Open | 5.19 |
| Bid | 0.00 x 168000 |
| Ask | 0.00 x 164000 |
| Day's range | 5.19 - 5.19 |
| 52-week range | 3.84 - 8.21 |
| Volume | |
| Avg. volume | 187 |
| Market cap | 1.133B |
| Beta (5Y monthly) | 1.96 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.00 |
| Earnings date | 01 Aug 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 21.27 |
GlobeNewswireBioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO® (berotralstat)
RESEARCH TRIANGLE PARK, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world evidence on the use of oral, once-daily ORLADEYO® (berotralstat) demonstrating that patients with hereditary angioedema (HAE) in the United States experience significant reductions in healthcare resource utilization (HRU) after beginning treatment with ORLADEYO. The study was presented in a poster at the 2024 International Society for Pharmacoeconomics and O
Simply Wall St.Analysts Are Updating Their BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Estimates After Its First-Quarter Results
BioCryst Pharmaceuticals, Inc. ( NASDAQ:BCRX ) defied analyst predictions to release its first-quarter results, which...
Insider MonkeyBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q1 2024 Earnings Call Transcript
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q1 2024 Earnings Call Transcript May 6, 2024 BioCryst Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.31 EPS, expectations were $-0.23. BCRX isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, and welcome […]
